This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Conditions
- Non Small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
- Pancreas Adenocarcinoma
- Biliary Tract Cancer
- Prostate Cancer
- Urothelial Carcinoma
- Colorectal Cancer
- Triple Negative Breast Cancer
- High Grade Ovarian Serous Adenocarcinoma
- Diffuse Large B Cell Lymphoma
- Renal Cell Cancer Metastatic
Interventions
Sponsor
Zumutor Biologics Inc.